BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 16, 2010
app pub date -
Jun 7, 2010
filing date -
Jun 9, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A method of diagnosis of cardiovascular disease (CVD) an immunoassay to measure aggrecan fragments in said sample, and association of an elevation above a normal level with the presence of CVD, is conducted by contacting aggrecan fragments in said sample with an first antibody reactive with an N-terminal first epitope formed by cleavage of aggrecan by a proteinase and with a second antibody reactive with a second aggrecan epitope which is present in aggrecan at a location in the C-terminal direction from the location of said N-terminal epitope, and measuring the extent of simultaneous binding of both antibodies.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully